Companies / Brazil
If you would like to subscribe to Americas Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Americas Pharma & Healthcare Insight please click on the trial link below.
Multinationals Respond To Epidemiological Imperatives
November 2006 | Company Finance AlertSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Americas Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Americas Pharma & Healthcare Insight please click on the trial link below.
The activities of two international pharmaceutical companies highlight the increasingly 'Western' disease trends driving the Brazilian market. Data from local drug industry association Febrafarma suggest that Anglo-Swedish firm AstraZeneca continues to grow its market share in Brazil. The firm's local unit reported sales of BRL592.8mn (US$277.2mn) for the first nine months of 2006 - a year-on-year rise of 13.8%. This compares to an overall rate of expansion in the market, expressed in local currency terms, of just 5.4%.